Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma : A lifetime cost-effectiveness analysis
✍ Scribed by Andrea Messori; Michele Cecchi; Paola Becagli; Sabrina Trippoli
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 61 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
medullary recurrence in certain ethnic groups will be the field have read the article. I agree that there is no proof that all-trans retinoic acid (ATRA) therapy confirmed by further observation and analysis of recurrence in the large cooperative group studying APL.
predisposes patients to the development of extramedullary recurrence and that point is made in the ''Con-Biologic effects of ATRA are characterized by differentiation of the malignant cell into a mature cell.
clusions'' section in the abstract of the article. Others take the opposite point of view, 2 and only time will The AML M3 cells secrete interleukin (IL)-1b, IL-6, IL-8, and tumor necrosis factor-a and a stimulatory effect tell, as Drs. Maloisel et al. state, whether ATRA does or does not facilitate extramedullary infiltration of leu-of ATRA on these cytokines expression can be suspected during the terminal differentiation of leukemic kemia in patients with APL. cells. Indeed, ATRA increases in vitro IL-1b and IL-6 secretion in these cells undergoing differentiation. 4 IL-Pharmacoeconomic Profile of therapy may alter the pattern of recurrence in some Paclitaxel as a First-Line patients with APL.